News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

02/07/2018 | Eberhard Karls Universität Tübingen

Alzheimer’s research on mice – intracellular calcium store malfunction leads to brain hyperactivity

Physiologists at the University of Tübingen discover the mechanism leading to increased release of neurotransmitters – and potential new approaches to treatment
02/05/2018 | Curetis GmbH

Curetis Group: Ares Genetics Receives Funding Commitment For EUR 1.6 Mio. Project

Curetis N.V., a developer of next-level molecular diagnostic solutions, today announced that Ares Genetics GmbH (Vienna, Austria), a wholly-owned subsidiary of Curetis, has received notice from the Austrian Research Promotion Agency (FFG) that it has been awarded a grant for a EUR 1.6 million research project.
01/30/2018 | Eberhard Karls Universität Tübingen

What Magnetic Fields Do in the Brain – And How to Observe It

Tübingen Neuroscientists develop method to better understand transcranial magnetic stimulation (TMS)
01/19/2018 | Eberhard Karls Universität Tübingen

Promising malaria medication tested

New combination of drugs proves effective and well-tolerated – Further studies planned
01/19/2018 | Exyte

M+W Products celebrates ground-breaking ceremony for its new head offices

The new company head offices of M+W Products GmbH are being built in Renningen. On January 19, the long-established company is celebrating a groundbreaking ceremony to mark the start of construction work at the new Raite industrial estate. In addition to the invited guests on site, live transmission to the existing company building will ensure that...
01/10/2018 | Eberhard Karls Universität Tübingen

Immune response to bacteria: Distinguishing helpers from harmers

University of Tübingen microbiologists discover the mechanism staphylococci use to lull our immune systems.
01/10/2018 | CureVac AG

CureVac Highlights Key 2018 Corporate Milestones and Outlook

CureVac AG, a clinical-stage biopharmaceutical company pioneering mRNA-based drugs, today outlined key 2018 milestones in conjunction with its presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. The Company highlighted its clinical development milestones and strategy for the year, including plans to initiate clinical...
01/10/2018 | Curetis GmbH

Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Company is advancing its strategic alliance in NGS-based infectious disease testing.
01/08/2018 | Curetis GmbH

Curetis Expects Near-Term FDA Decision on De Novo Request

Curetis N.V. (the "Company" and, together with Curetis USA Inc. and Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today provided a status update on the FDA De Novo filing for the Company’s Unyvero System and LRT Cartridge for the diagnosis of lower respiratory tract infections.
01/04/2018 | CureVac AG

CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeuti...

Hope in the fight against multi-resistant germs

Researchers from the Universities of Stuttgart and Tübingen prove the effectiveness of new types of antibiotics.

Microalgae Ready for Space

The University of Stuttgart hands over photobioreactor chambers for space experiment on the ISS

Nerve Cells on the ISS: University of Hohenheim Examines How Cells Grow without Gravity

Project NEUROBOX sends human nerve cells to the International Space Stations / Project looks at how nervous systems develop in space / Team accompanies mission with journals How would the first person born in space develop? While it sounds like a question for a science fiction novel, it is the background of a current research project at the Univers...
10/19/2017 | CureVac AG

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types / CureVac to receive an upfront payment of $50 million and an equity investment of €45 million
08/21/2017 | immatics biotechnologies GmbH

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA1...
08/16/2017 | CureVac AG

Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

Data validate the strength of CureVac’s RNAntibody® technology to produce high and sustained levels of antibody production in a variety of disease indications

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

Data from phase I clinical trial of CureVac’s RNActive® prophylactic vaccine technology in rabies demonstrates for the first time an induction of boostable functional antibodies against a viral antigen when administered via needle-free injection Cu...